Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|December 6, 2019
GE Healthcare Life Sciences Launches New Software for Cell Therapy Workflow
Author(s)Pharmaceutical Technology Editors
The new software lets users choose the volume and cell concentration from initial cell preparation through transduction to final resuspension, without compromising cell viability and virus stability.
Advertisement
GE Healthcare Life Sciences announced the launch of its SpinOculation C-Pro Protocol Software for cell therapy workflow on Dec. 2, 2019.
The new software is part of the Sepax C-Pro Cell Processing System and, when used with the Sepax C-Pro instrument and CT-60.1 single-use kit, lets users choose the volume and cell concentration from initial cell preparation through transduction to final resuspension, without compromising cell viability and virus stability, according to a company press release. The software also closes and automates the cell transduction step, reduces manipulations, and adjusts open system parameters.
“Cell-therapy manufacturing is complex and requires advanced technologies,” said Catarina Flyborg, general manager, Cell and Gene Therapy, GE Healthcare Life Sciences, in the press release. “GE Healthcare Life Sciences continues to invest and develop the digital solutions needed to advance cell and gene therapies. The SpinOculation C-Pro software application automates and simplifies a critical step in the cell therapy workflow and helps accelerate the development of next generation therapeutics.”
The SpinOculation C-Pro Protocol Software is now available worldwide.
Source:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement